Dy­nacure to merge with Flamin­go, re­join­ing two Io­n­is-af­fil­i­at­ed biotechs

Dy­nacure still isn’t get­ting on­to the pub­lic mar­kets, but the French-US biotech is com­bin­ing with an­oth­er Io­n­is-al­lied drug de­vel­op­er to stay afloat.

Af­ter its lead drug failed a rare mus­cle dis­ease tri­al last year, Dy­nacure is now merg­ing with Flamin­go Ther­a­peu­tics, the com­pa­nies said Thurs­day. Dy­nacure had tried go­ing pub­lic in 2021 at a range of $15 to $17 per share, but with­drew those plans in sum­mer 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER